| P2093 | author name string | Frederic D Bushman | |
| P2860 | cites work | Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients | Q36812729 |
| | Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing | Q39005853 |
| | HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. | Q40050048 |
| | Analysis of avian leukosis virus DNA and RNA in bursal tumors: Viral gene expression is not required for maintenance of the tumor state | Q45802546 |
| | A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 |
| | Gene therapy insertional mutagenesis insights | Q45871758 |
| | Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy | Q45874789 |
| | Role of endogenous retroviruses as mutagens: the hairless mutation of mice | Q48318780 |
| | The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases | Q48361328 |
| | Murine T lymphomas in which the cellular myc oncogene has been activated by retroviral insertion | Q48390929 |
| | Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells | Q58889356 |
| | A quantitative approach for measuring the reservoir of latent HIV-1 proviruses | Q91284113 |
| | Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges | Q92283987 |
| | Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia | Q24618997 |
| | Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma | Q28276048 |
| | Efficacy of gene therapy for X-linked severe combined immunodeficiency | Q28288838 |
| | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 | Q28290118 |
| | Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity | Q33413888 |
| | Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy | Q33450585 |
| | Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease | Q34094502 |
| | HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection | Q34502840 |
| | Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy | Q34607544 |
| | HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells | Q34672568 |
| | A modified γ-retrovirus vector for X-linked severe combined immunodeficiency | Q34763502 |
| | RTCGD: retroviral tagged cancer gene database | Q34923778 |
| | HIV-1 integration landscape during latent and active infection | Q35211469 |
| | On the mechanism of retrovirus-induced avian lymphoid leukosis: deletion and integration of the proviruses | Q35374238 |
| | Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque | Q35848273 |
| | Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy | Q35916142 |
| P433 | issue | 2 | |
| P304 | page(s) | 352-356 | |
| P577 | publication date | 2020-01-07 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones | |
| P478 | volume | 28 | |